Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia

NCT02072811 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: DAC
DRUG: CLAG
DRUG: Consolidation, I HAM cycle
DRUG: II Consolidation HiDAraC
DRUG: Consolidation, III HiDAraC cycle

Sponsor

dr hab. n. med. Agnieszka Wierzbowska

Collaborators

[object Object]
[object Object]